Terence Kelly appointed CEO of ATAI platform company Perception Neuroscience

February 13, 2020 Articles 7:21 pm

Today, ATAI Life Sciences, a global biotech platform that envisions an end to mental illnesses, announced the appointment of Dr. Terence Kelly as Chief Executive Officer of Perception Neuroscience, an ATAI biopharmaceutical company developing arketamine for treatment resistant depression.

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit